The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Menees, Stacy B, Maneerattannaporn, Monthira, Kim, Hyungjin Myra, Chey, William D·2012·American Journal of Gastroenterology
DOI 10.1038/ajg.2011.355

Cited by (283)

Items 101–200 of 283

  1. Prevalence, incidence, and risk factors of intestinal parasites in Danish primary care patients with irritable bowel syndrome
    Anne Line Engsbro, Christen Rune Stensvold, Henrik Vedel Nielsen, Peter M. Bytzer · 2013 · Scandinavian Journal of Infectious Diseases
  2. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome
    J. Kane, A. Ford · 2016 · Expert Review of Gastroenterology & Hepatology
  3. Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.
    M. Camilleri, A. Ford · 2017 · Handbook of Experimental Pharmacology
  4. Pharmacological agents currently in clinical trials for disorders in neurogastroenterology
    Michael Camilleri · 2013 · Journal of Clinical Investigation
  5. Pharmacologic Therapies in Gastrointestinal Diseases
    Rena K. Fox, Thiruvengadam Muniraj · 2016 · Medical Clinics of North America
  6. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases
    Jasmohan Singh Bajaj, Giovanni Barbara, Herbert L. DuPont, Fermín Mearin, Antonio Gasbarrini, Jan F. Tack · 2018 · Digestive and Liver Disease
  7. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
    Anthony J Lembo, Satish S.C. Rao, Zeev Heimanson, Mark Pimentel · 2020 · Clinical and Translational Gastroenterology
  8. New treatments for IBS
    Magnus Halland, Nicholas J. Talley · 2012 · Nature Reviews Gastroenterology & Hepatology
  9. Microbiome, antibiotics and irritable bowel syndrome
    Omer F. Ahmad, Ayesha Akbar · 2016 · British Medical Bulletin
  10. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
    Xiaojun Zhuang, Zhenyi Tian, Mei Luo, Lishou Xiong · 2020 · BMC Gastroenterology
  11. Lactobacillus plantarum PS128 Ameliorated Visceral Hypersensitivity in Rats Through the Gut–Brain Axis
    Yen-Wenn Liu, Yen‐Po Wang, Hsu-Fang Yen, Pei-Yi Liu, Wen-Jian Tzeng, Chia-Fen Tsai, Han‐Chieh Lin, Fa‐Yauh Lee, One-Jang Jeng, Ching‐Liang Lu et al. · 2019 · Probiotics and Antimicrobial Proteins
  12. Irritable Bowel Syndrome
    Elizabeth Jane Videlock, Lin Chang · 2016 · Wiley eBooks
  13. Microbiota, infecciones gastrointestinales, inflamación de bajo grado y antibioticoterapia en el síndrome de intestino irritable. Una revisión basada en evidencias
    Schmulson, M., Bielsa, M.V., Carmona-Sánchez, R., Hernández, A., López-Colombo, A., López Vidal, Y., Peláez-Luna, M., Remes-Troche, J.M., Tamayo, J.L., Valdovinos, M.A. · 2014 · Revista de Gastroenterología de México
  14. Updated review of current pharmacological and non‐pharmacological management of irritable bowel syndrome
    P. Rawla, Tagore Sunkara, J. P. Raj · 2018 · Life Science
  15. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders
    Hyo Jeong Lee, Jongkyoung Choi, Han Seung Ryu, Chang Hwan Choi, Eun Hee Kang, Kyung Sik Park, Yang Won Min, Kyoung Sup Hong · 2017 · Journal of Neurogastroenterology and Motility
  16. 3-Hydroxyflavone and structural analogues differentially activate pregnane X receptor: Implication for inflammatory bowel disease
    Aik Jiang Lau, Thomas K. H. Chang · 2015 · Pharmacological Research
  17. Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population
    Jacqui Eales, Peter G. Gibson, Peter James Whorwell, John Edward Kellow, Ann Yellowlees, Richard H.J. Perry, Mary Edwards, Sarah King, Hannah Wood, Julie Glanville · 2016 · Therapeutic Advances in Gastroenterology
  18. Side effects are incompletely reported among systematic reviews in gastroenterology
    Suzanne E. Mahady, Timothy E. Schlub, Lisa Anne Bero, David Moher, David I Tovey, Jacob George, Jonathan C. Craig · 2014 · Journal of Clinical Epidemiology
  19. Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
    Sandro La Vignera, Enzo Saretto Dante Vicari, Roberto Castiglione, Rosita Angela Condorelli, L. O. Vicari, Aldo Eugenio Calogero · 2014 · Asian Journal of Andrology
  20. Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
    Su-Hyun Bae, Kwang Jae Lee, Young‐Sang Kim, Kyu-Nam Kim · 2015 · Journal of Korean Medical Science
  21. Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spaish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR)
    Instituto de Investigación Sanitaria Gregorio Marañón Servicio de Microbiología Clínica y E. Infecciosas, Emilio Bouza, José María Aguado, Luís Alcalá, Benito Almirante, Patricia Alonso‐Fernández, Marcío Borges-Sa, Javier Cobo, Jordi Guardiola, Juan Pablo Horcajada et al. · 2020 · Revista Española de Quimioterapia
  22. Bile acids and FXR in functional gastrointestinal disorders
    Paula Mosińska, Adrian Szczepaniak, Jakub Fichna · 2018 · Digestive and Liver Disease
  23. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
    Doron Boltin, Tsachi Tsadok Perets, Einav Shporn, Shoshana Aizic, Sigal Levy, Yaron Niv, Ram M. Dickman · 2014 · Annals of Clinical Microbiology and Antimicrobials
  24. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease
    Kristi A. Leonard, Lisa A. Madge, Paul J. Krawczuk, Aihua Wang, Kevin D. Kreutter, Genesis M. Bacani, Wenying Chai, Russell C. Smith, Mark S. Tichenor, Michael C. Harris et al. · 2020 · Journal of Medicinal Chemistry
  25. Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome
    Brooks D. Cash · 2014 · Current Medical Research and Opinion
  26. THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review
    Joaquim Prado P. Moraes-Filho, Eamonn M.M. Quigley · 2015 · Arquivos de Gastroenterologia
  27. Recent advances in pharmacological treatment of irritable bowel syndrome.
    Geórgia, Lazaraki, Grigoris, Chatzimavroudis, Panagiotis, Katsinelos · 2014 · World Journal of Gastroenterology
  28. Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation
    Francesca Romana Ponziani, Silvia Pecere, Loris Riccardo Lopetuso, Franco Scaldaferri, Giovanni Cammarota, Antonio Gasbarrini · 2016 · Expert Opinion on Drug Safety
  29. Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia
    Vladimir B. Grinevich, Yu. A. Kravchuk, V. I. Ped, Evgenii I. Sas, S. P. Salikova, Губонина Ирина Владимировна, Tkachenko Ei, Stanislav I. Sitkin, Л. Б. Лазебник, Е. В. Голованова · 2020 · Экспериментальная и клиническая гастроэнтерология
  30. Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases
    Andreas R. Muehler, Jason R. Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt · 2020 · World Journal of Gastrointestinal Pathophysiology
  31. Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome
    Jose Barboza, Nicholas J. Talley, Baharak Moshiree · 2014 · Drugs
  32. Metabolic syndrome, depression, and fibromyalgia syndrome prevalence in patients with irritable bowel syndrome
    Muharrem Bayrak · 2020 · Medicine
  33. Chronic Intestinal Pseudo-Obstruction: Is There a Connection with Gut Microbiota?
    Giulia Radocchia, Bruna Neroni, Massimiliano Marazzato, Elena Capuzzo, Simone Zuccari, Fabrizio Pantanella, Letizia Zenzeri, Melania Evangelisti, Francesca Vassallo, Pasquale Parisi et al. · 2021 · Microorganisms
  34. Anti-inflammatory and immunomodulatory activities of rifamycin SV
    Caridad Rosette, Fernando Buendia-Laysa, Seema Patkar, Luigi Moro, Giuseppe Celasco, Roberta Bozzella, Mauro Ajani, Mara Gerloni · 2013 · International Journal of Antimicrobial Agents
  35. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran.
    Mehdi Hayatbakhsh Abbasi, Mohammad Javad Zahedi, Sodaif Darvish Moghadam, Sara Shafieipour, Mahroo HayatBakhsh Abbasi · 2015 · Europe PMC (PubMed Central)
  36. Intestinal Microbiota
    Luis María Bustos Fernández, Juan Sebastian Lasa, Fernando Man · 2014 · Journal of Clinical Gastroenterology
  37. Close association between intestinal microbiota and irritable bowel syndrome
    W.-T. Fan, Chao Ding, Na Xu, Shuai Zong, P. Ma, Bing Gu · 2017 · European Journal of Clinical Microbiology & Infectious Diseases
  38. Pain in irritable bowel syndrome: Does anything really help?
    Joelle BouSaba, Wassel Sannaa, Michael Camilleri · 2021 · Neurogastroenterology & Motility
  39. Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome
    Teita Asano, Ken‐ichiro Tanaka, Arisa Tada, Hikaru Shimamura, Rikako Tanaka, Hiroki Maruoka, Mitsuko Takenaga, Tohru Mizushima · 2017 · Scientific Reports
  40. Non-Celiac Gluten Sensitivity and Irritable Bowel Disease: Looking for the Culprits
    Lemonica Koumbi, Όλγα Γιουλεμέ, Εmilia Vassilopoulou · 2020 · Current Developments in Nutrition
  41. A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence
    A. Papale, Robert Flattau, N. Vithlani, Deepti Mahajan, S. Nadella · 2024 · Journal of Clinical Medicine
  42. Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome
    Shilan Mozaffari, Shekoufeh Nikfar, Mohammad Reza Abdollahi · 2013 · Expert Opinion on Drug Metabolism & Toxicology
  43. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome
    Judy W. Nee, Mohammed Zakari, Anthony J Lembo · 2015 · Expert Opinion on Pharmacotherapy
  44. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome
    Lucrezia Laterza, Gianluca Ianiro, Iolanda Scoleri, Rosario Landi, Giovanni Bruno, Franco Scaldaferri, Eleonora Gaetani, Mariachiara Campanale, Antonio Gasbarrini · 2015 · Expert Opinion on Pharmacotherapy
  45. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome
    Eugenia Bruzzese, Marcella Pesce, Giovanni Sarnelli, Alfredo Guarino · 2018 · Expert Opinion on Drug Metabolism & Toxicology
  46. Irritable bowel syndrome – Diarrhoea
    Arnold M. Wald · 2012 · Best Practice & Research Clinical Gastroenterology
  47. Toward Restored Bowel Health in Rectal Cancer Survivors
    Gunnar Steineck, Heike Schmidt, Eleftheria Alevronta, Fei Sjöberg, Cecilia Bull, Dirk Vordermark · 2016 · Seminars in Radiation Oncology
  48. Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines
    Vladimir B. Grinevich, Л. Б. Лазебник, Yu. A. Kravchuk, В Г Радченко, Tkachenko Ei, А. М. Першко, Pavel Vasilievich Seliverstov, S. P. Salikova, Konstantin V. Zhdanov, Konstantin V. Kozlov et al. · 2023 · Экспериментальная и клиническая гастроэнтерология
  49. Associations between irritable bowel syndrome and non-alcoholic fatty liver disease: A systematic review
    Jareth Jun Jie Ng, Wai Mun Loo, Kewin Tien Ho Siah · 2023 · World Journal of Hepatology
  50. Belgian consensus on irritable bowel syndrome
    Sébastien Kindt, H Louis, Heiko U. De Schepper, Joris Arts, Philip Caenepeel, Danny A. De Looze, Ariane Gerkens, Tom Holvoet, P Latour, Tania Mahler et al. · 2022 · Acta gastro-enterologica belgica
  51. Small Intestinal Bacterial Overgrowth and Childhood Malnutrition: A Comprehensive Review of Available Evidence
    Cristina Roxana Mareș, Maria Oana Săsăran, Cristina Oana Mărginean · 2024 · Nutrients
  52. The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements
    Justin CY Wu, Annie On On Chan, YW Chan, Gordon CL Cheung, TK Cheung, AMBROSE CHI‐PONG KWAN, Vincent KS Leung, Arthur D. P. Mak, Stephen Cho Wing Sze, Raymond S. M. Wong · 2017 · Hong Kong Medical Journal
  53. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
    Christopher Chang · 2018 · Clinical and Experimental Gastroenterology
  54. A meta-analysis of randomized controlled trials evaluating the effectiveness of fecal microbiota transplantation for patients with irritable bowel syndrome
    Yu Wang, Yongmei Hu, Ping Shi · 2024 · BMC Gastroenterology
  55. The safety of novel drugs used to treat irritable bowel syndrome
    Shilan Mozaffari, S. Nikfar, M. Abdollahi · 2014 · Expert Opinion on Drug Safety
  56. Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders
    Agata Szymaszkiewicz, Martin Storr, Jakub Fichna, Marta Zielińska · 2018 · Neurogastroenterology & Motility
  57. Irritable bowel syndrome
    Vladimir T Ivashkin, Yu. A. Shelygin, Е. К. Baranskaya, Ачкасов Сергей Иванович, С. С. Белоус, Е. Д. Белоусова, A. G. Beniashviili, S. V. Vasiliev, E. G. Grigoriev, Nikolay V. Kostenko et al. · 2022 · Koloproktologia
  58. Correlating the Gut Microbiome to Health and Disease
    Tatiana Milena Marques, Savanne Holster, Rebecca Wall, Julia König, Robert J. Brummer, Willem M. de Vos · 2016 · Elsevier eBooks
  59. Irritable bowel syndrome: current and emerging treatment options.
    Lauren Peyton, Joy Greene · 2014 · PubMed Central
  60. Role of Small Intestinal Bacterial Overgrowth in Functional Gastrointestinal Disorders
    Chang Hwan Choi, Sae Kyung Chang · 2015 · Journal of Neurogastroenterology and Motility
  61. Fecal Incontinence in Adults: New Therapies
    John William Blackett, Adil E. Bharucha · 2025 · The American Journal of Gastroenterology
  62. Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection
    Paul Feuerstadt, Simon J. Hong, Lawrence J. Brandt · 2019 · Digestive Diseases and Sciences
  63. The relationship between small intestinal bacterial overgrowth and constipation in children – a comprehensive review
    Cristina Roxana Mareș, Maria Oana Săsăran, Cristina Oana Mărginean · 2024 · Frontiers in Cellular and Infection Microbiology
  64. Functional Abdominal Bloating and Gut Microbiota: An Update
    Salvatore Crucillà, Federico Caldart, Marco Michelon, Giovanni Marasco, Andrea Costantino · 2024 · Microorganisms
  65. Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients?
    Amit Kumar Gupta, William D. Chey · 2016 · The American Journal of Gastroenterology
  66. Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review
    Michael Camilleri, Saam Dilmaghani · 2023 · Pharmacology & Therapeutics
  67. Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
    Enzo Saretto Dante Vicari, Michele Salemi, Giuseppe Sidoti, Mariano Malaguarnera, Roberto Castiglione · 2017 · Nutrients
  68. Update on the Role of Rifaximin in Digestive Diseases
    Dan Lucian Dumitrascu, Игорь Геннадьевич Бакулин, Annalisa Berzigotti, Marilia L. Cravo, Laura Gombošová, Milan Lukáš, Anna Maria Pietrzak, José María Remes-Troche, Manuel Romero‐Gómez, Mercedes Amieva‐Balmori et al. · 2023 · Journal of Gastrointestinal and Liver Diseases
  69. Adenosine A2B Receptors: An Optional Target for the Management of Irritable Bowel Syndrome with Diarrhea?
    Teita Asano, Mitsuko Takenaga · 2017 · Journal of Clinical Medicine
  70. THE EFFECT OF PROBIOTIC FERMENTED MILK THAT INCLUDES BIFIDOBACTERIUM LACTIS CNCM I-2494 ON THE REDUCTION OF GASTROINTESTINAL DISCOMFORT AND SYMPTOMS IN ADULTS: A NARRATIVE REVIEW.
    Dan Linetzky Waitzberg, Flávio Antônio Quilici, Sender Michzputen, Maria do Carmo Friche Passos · 2015 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  71. Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome
    Seok‐Hoon Lee, Cho-Rong Kim, Kyu-Nam Kim · 2018 · The American Journal of the Medical Sciences
  72. Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome
    E. Shah, Mark Pimentel · 2014 · Alimentary Pharmacology and Therapeutics
  73. Update in diagnosis and management of irritable bowel syndrome
    Tsung-Hsing Hung, Chih-Ying Wang, Hsing-Feng Lee · 2023 · Tzu-Chi Medical Journal
  74. Refractory inflammatory bowel disease—could it be an irritable bowel?
    Jie Meng, Anurag Agrawal, Peter James Whorwell · 2012 · Nature Reviews Gastroenterology & Hepatology
  75. Irritable Bowel Syndrome and Female Patients.
    L. Harris, S. Umar, Noemi J. Baffy, M. Heitkemper · 2016 · Gastroenterology Clinics of North America
  76. Probiotics, prebiotics, antibiotic, Chinese herbal medicine, and fecal microbiota transplantation in irritable bowel syndrome
    Ying He, Rui Xu, Wei Wang, Jie Zhang, Xiaoyu Hu · 2020 · Medicine
  77. Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Zarghuna Khan, Saad Khalid Khan, Ibrahim Reyaz, Hemalatha Anam, Osama Ijaz, Ilqa Attique, Zoha Shahzad, Faraz Saleem · 2023 · Cureus
  78. Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome
    Kee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, Jing Yi Leong, Wah Loong Chan, Xin Hui Khoo, Kim Leng Wong, Sarala Panirsheeluam, Vicraman Natarajan, Ai Kah Ng et al. · 2025 · Alimentary Pharmacology & Therapeutics
  79. New treatment options for irritable bowel syndrome with predominant diarrhea
    H. C. Weber · 2016 · Current Opinion in Endocrinology, Diabetes & Obesity
  80. Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats
    María Jesús Rodríguez‐Sojo, Jorge García-García, Antonio Jesús Ruiz‐Malagón, Patricia Diez‐Echave, Laura Hidalgo‐Garcia, José Alberto Molina‐Tijeras, Elena González-Lozano, Laura López-Escánez, Maria Elena Rodríguez‐Cabezas, Marí­a José Rodrí­guez et al. · 2022 · Nutrients
  81. Rifaximin Improves Visceral Hyperalgesia via TRPV1 by Modulating Intestinal Flora in the Water Avoidance Stressed Rat
    Changqing Yang, Xiaoshu Guo, Ji-Li, Zibai Wei, Li Zhao, Zhao Gan-ting, Shu-ting Sheng · 2020 · Gastroenterology Research and Practice
  82. Effects of the antibiotic rifaximin on cortical functional connectivity are mediated through insular cortex
    Davide Sometti, Chiara Ballan, Huiying Wang, Christoph Braun, Paul Enck · 2021 · Scientific Reports
  83. Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (2nd edition)
    Vladimir B. Grinevich, Yu. A. Kravchuk, V. I. Ped, Evgenii I. Sas, S. P. Salikova, Губонина Ирина Владимировна, Tkachenko Ei, Stanislav I. Sitkin, Л. Б. Лазебник, Е. В. Голованова et al. · 2021 · Экспериментальная и клиническая гастроэнтерология
  84. Comparison of Rifaximin Monotherapy and Rifaximin Combined with Probiotics in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial
    Chang Kyo Oh, Hwe Hoon Chung, Yu Jin Kim, Jin Bae Kim · 2025 · Nutrients
  85. European Consensus on Functional Bloating and Abdominal Distension—An ESNM/UEG Recommendations for Clinical Management
    Chloé Melchior, Heinz Florian Hammer, Serhat Bor, Elizabeth Barba, Indira Benjak Horvat, Altay Çelebi, Vasile Liviu Drug, Dan Lucian Dumitrascu, İsmail Hakkı Kalkan, Goran Hauser et al. · 2025 · United European Gastroenterology Journal
  86. Rifaximin for Pertuzumab-Related GI Toxicities
    Aixa Elena Soyano, Gina A. Reynolds, Alvaro Moreno‐Aspitia, Saranya Chumsri · 2017 · Frontiers in Oncology
  87. Targeted pharmacotherapy of irritable bowel syndrome.
    A. Arokiadoss, H. Weber · 2021 · Current Opinion in Endocrinology, Diabetes & Obesity
  88. Rifamycins
    Melanie Jane Maslow, Cynthia Portal‐Celhay · 2015 · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
  89. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
    Kamesh Gupta, Harparam Singh Ghuman, Shivani Handa · 2017 · Clinical Medicine Insights Gastroenterology
  90. A new perspective in the prevention and treatment of antitumor therapy-related cardiotoxicity: Intestinal microecology
    Chenchen Meng, Xiaoming Wang, Lu Fan, Yajie Fan, Zhipeng Yan, Yunjiao Wang, Yanyang Li, Junping Zhang, Shichao Lv · 2023 · Biomedicine & Pharmacotherapy
  91. Efficacy of a Quebracho, Conker Tree, and M. balsamea Willd Blended Extract in a Randomized Study in Patients with Irritable Bowel Syndrome with Constipation
    K. Brown, Brandi Scott-Hoy, L. Jennings · 2015 · Journal of Gastroenterology and Hepatology Research
  92. Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating
    Kichul Yoon, Nayoung Kim, Ju Yup Lee, Dong Hyun Oh, A Young Seo, Chang Yong Yun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee · 2018 · Korean Journal of Gastroenterology
  93. Irritable bowel syndrome: the problem and the problem of treating it – is there a role for probiotics?
    Antonieta R. Santos, Peter James Whorwell · 2014 · Proceedings of The Nutrition Society
  94. Mechanism-Oriented Therapy of Irritable Bowel Syndrome
    Juan Ramon Malagelada, Carolina Malagelada · 2016 · Advances in Therapy
  95. The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study
    E P Yakovenko, Т.В. Строкова, Alexander N. Ivanov, A V Iakovenko, Гиоева Ирина Заурбековна, М. А. Алдиярова · 2022 · Terapevticheskii arkhiv
  96. An animal model of limitation of gut colonization by carbapenemase-producing Klebsiella pneumoniae using rifaximin
    Eleni Xenofontos, Georgios Renieris, Maria Kalogridi, Dionyssia-Eirini Droggiti, Kalliopi D. Synodinou, Georgia Damoraki, Panagiotis Koufargyris, Labros Sabracos, Evangelos J. Giamarellos‐Bourboulis · 2022 · Scientific Reports
  97. Identification of the Microbiota in the Aging Process
    Amar Sarkar, Capecomorin S. Pitchumoni · 2017 · Elsevier eBooks
  98. The clinical outcomes of gut-brain axis (GBA) microbiota influence on psychiatric disorders
    Masoumeh Navidinia, Mehdi Goudarzi, Elahe Seyfi · 2023 · Iranian Journal of Microbiology
  99. Das Reizdarmsyndrom in der hausärztlichen Praxis
    Johanna S. Bobardt, M. Freitag · 2023 · Zeitschrift für Allgemeinmedizin
  100. Microbial Influences on Irritable Bowel Syndrome
    Eamonn M.M. Quigley · 2025 · Gastroenterology Clinics of North America